Error in Supplement 3

Дата публикации: 01-10-2026 00:00:00

In the Original Investigation titled “First-Line Serplulimab in Extensive-Stage Small Cell Lung Cancer: Secondary Analysis of the ASTRUM-005 Phase 3 Randomized Clinical Trial,” published online June 4, 2026, and in the August 2026 issue, eTable 6 was erroneously excluded from Supplement 3. Supplement 3 has been updated to include eTable 6. This article was corrected online.

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	Errors in Figures	0	12.94	01-07-2026
2	Toripalimab Plus Chemotherapy as a First-Line Therapy for Extensive-Stage Small Cell Lung Cancer	0	14.28	01-01-2025
3	Time to Sustained CEA Elevation From Start of First-Line Therapy Predicts Initial Treatment Efficacy and Clinical Outcomes in Lung Adenocarcinoma	0	17.69	20-08-2026
4	Achievement of Pathological Complete Response with Neoadjuvant Ensartinib in a Patient with Locally Advanced ALK-Rearranged Lung Squamous Cell Carcinoma: A Case Report and Literature Review	0	5	16-07-2026
5	A Smoking-Independent CT Radiomic Signal Predicts EGFR Mutation in Non-Small-Cell Lung Cancer Under a Pre-Registered, Cross-Validated Design	0	29.94	19-08-2026
6	Combined Furmonertinib and Intrathecal Chemotherapy for Leptomeningeal Metastasis from Non-Small Cell Lung Cancer: Efficacy, Safety, and CSF Drug Concentrations	0	16.9	07-08-2026
7	Aptamer-Based Capture of CXCR4-Positive Circulating Tumor Cells for Postoperative Recurrence and Metastasis Risk Assessment in Non-Small Cell Lung Cancer	0	5	16-07-2026
8	EMA Recommends Extension of Therapeutic Indications for Serplulimab	0	13.88	31-07-2026
9	Treatment with Encorafenib Plus Cetuximab Plus FOLFIRI Improves Outcomes in Patients with BRAF V600E-mutated mCRC	0	12.4	23-07-2026

Классификация: . Схожих патентов: 0. Схожих новостей: 9. Тональность: 0. Информативность: 19.38. Источник: jamanetwork.com.